Psoriatic Arthritis
Controlled disease, reproductive counseling ‘critical’ for both males, females with PsA
Both men and women of reproductive age with psoriatic arthritis who are hoping to be parents should consult their medical team and adhere to medications, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.
Overlap in PsA, nonradiographic axSpA, reactive arthritis make for ‘challenging’ diagnosis
Shared features and clinical presentations can make diagnosis and management of psoriatic arthritis, non-radiographic axial spondyloarthritis and reactive arthritis particularly challenging, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.
Joint pain in psoriasis, PsA driving analgesic opioid use
Biologic use in psoriasis reduces risk for psoriatic arthritis
The use of biological disease-modifying antirheumatic drugs in patients with psoriasis reduces the risk for psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.
Cardiovascular risk in PsA greater for new users of IL-12/23, IL-17 vs. TNF inhibitors
Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.
Guselkumab 100 mg improves fatigue in psoriatic arthritis through 1 year
Guselkumab 100 mg administered every 4 or 8 weeks produced “meaningful and sustained” improvements in fatigue through 1 year in patients with psoriatic arthritis, according to data published in Arthritis & Research & Therapy.
Ustekinumab, TNF inhibitors exhibit similar remission, disease activity responses in PsA
Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.
Methotrexate boosts psoriatic arthritis remission rates for both adalimumab, infliximab
Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.
Guselkumab sustains improvements in PsA with sacroiliitis through 1 year
Guselkumab administered once every 4 or 8 weeks improved axial outcomes in patients with psoriatic arthritis who have sacroiliitis through week 52, according to data published in The Lancet Rheumatology.
Infection risk lower with ustekinumab than other biologics, apremilast in PsA, psoriasis
Patients with psoriasis or psoriatic arthritis treated with ustekinumab demonstrated a 1.4- to 3-times lower risk for hospitalization with serious infections than those who received other biologics or apremilast, according to data.